At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 397 enrolled
Drug / intervention
AL-4943A ophthalmic solution +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Center, Randomized, Double-Masked, Vehicle and Active Controlled, Parallel-Group Efficacy and Safety Study of AL-4943A Ophthalmic Solution, 0.77% in Patients With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge (CAC) Model
In Brief
A Phase 3 clinical trial evaluating AL-4943A ophthalmic solution, AL-4943A vehicle, and 1 other intervention for Allergic Conjunctivitis. Completed, enrolled 397 participants.
Detailed Summary
The purpose of this study was to assess the safety and efficacy of AL-4943A ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis using the Conjunctival Allergen Challenge (CAC) model.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergic Conjunctivitis
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedNov 2011
Enrollment StartJan 2012
Primary CompletionMar 2012
TodayJul 2026
First PostedNov 24, 2011
Enrollment StartJan 1, 2012
Primary CompletionMar 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 14.6 years ago
Interventions
AL-4943A ophthalmic solutiondrug
AL-4943A vehicledrug
Inactive ingredients used as placebo
Olopatadine hydrochloride ophthalmic solution, 0.2%drug